Evidence map›Paper›PMID 22247553›Full record

ArticleThe Journal of biological chemistry2012

Fibronectin induces endothelial cell migration through β1 integrin and Src-dependent phosphorylation of fibroblast growth factor receptor-1 at tyrosines 653/654 and 766.

Li Zou, Sheng Cao, Ningling Kang, Robert C Huebert, Vijay H Shah

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers.

0numbers the graph read from it
0cells of the map it votes in
54citing papers in PubMed
3.9field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

54 citing papers in PubMed, 104 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. The matricellular protein CCN3 supports lung endothelial homeostasis and function.American journal of physiology. Lung cellular and molecular physiology · 2023
    Article
  16. A novel small molecule RK-019 inhibitsFrontiers in pharmacology · 2022
    Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Li ZouGastroenterology Research Unit and Cancer Cell Biology Program, Mayo Clinic, Rochester, Minnesota 55905, USA.
Sheng Cao
Ningling Kang
Robert C Huebert
Vijay H Shah
Mayo Clinic · US

Funding

PILOT AND FEASIBILTY PROGRAMP30DK084567 · NIDDK · MAYO CLINIC ROCHESTER · PI Samar Ibrahim · 2009 to 2026
$22.2M
Molecular Mechanisms of Portal HypertensionR01DK059615 · NIDDK · MAYO CLINIC ROCHESTER · PI SHAH, VIJAY H. · 2002 to 2023
$6.4M
HEPATIC STELLATE CELL REGULATION OF METASTATIC GROWTH IN THE LIVERR01CA160069 · NCI · UNIVERSITY OF MINNESOTA · PI NINGLING KANG · 2011 to 2026
$5.2M
Molecular Mechanisms of Liver Fibrosis (Diversity Supplement)R37AA021171 · NIAAA · MAYO CLINIC ROCHESTER · PI VIJAY H. SHAH · 2019 to 2026
$3.0M
Molecular Mechanisms of Liver FibrosisR01AA021171 · NIAAA · MAYO CLINIC ROCHESTER · PI SHAH, VIJAY H. · 2012 to 2018
$2.5M
Mechanisms of Nitric Oxide Signaling in Vascular RemodelingR01HL086990 · NHLBI · MAYO CLINIC ROCHESTER · PI SHAH, VIJAY H. · 2008 to 2011
$1.5M
Molecular Mechanisms of Portal HypertensionR56DK059615 · NIDDK · MAYO CLINIC ROCHESTER · PI SHAH, VIJAY H · 2007 to 2007
$378k
NCI NIH HHS R01 CA160069NHLBI NIH HHS HL086990NHLBI NIH HHS R01 HL086990NIAAA NIH HHS AA021171-01NIAAA NIH HHS R01 AA021171NIAAA NIH HHS R37 AA021171NIDDK NIH HHS DK59615-06NIDDK NIH HHS P30 DK084567NIDDK NIH HHS P30DK084567NIDDK NIH HHS R01 DK059615NIDDK NIH HHS R56 DK059615
6 · The paper itself

Abstract

The extracellular matrix microenvironment regulates cell phenotype and function. One mechanism by which this is achieved is the transactivation of receptor tyrosine kinases by specific matrix molecules. Here, we demonstrate that the provisional matrix protein, fibronectin (FN), activates fibroblast growth factor (FGF) receptor-1 (FGFR1) independent of FGF ligand in liver endothelial cells. FN activation of FGFR1 requires β1 integrin, as evidenced by neutralizing antibody and siRNA-based studies. Complementary genetic and pharmacologic approaches identify that the non-receptor tyrosine kinase Src is required for FN transactivation of FGFR1. Whereas FGF ligand-induced phosphorylation of FGFR1 preferentially activates ERK, FN-induced phosphorylation of FGFR1 preferentially activates AKT, indicating differential downstream signaling of FGFR1 in response to alternate stimuli. Mutation analysis of known tyrosine residues of FGFR1 reveals that tyrosine 653/654 and 766 residues are required for FN-FGFR1 activation of AKT and chemotaxis. Thus, our study mechanistically dissects a new signaling pathway by which FN achieves endothelial cell chemotaxis, demonstrates how differential phosphorylation profiles of FGFR1 can achieve alternate downstream signals, and, more broadly, highlights the diversity of mechanisms by which the extracellular matrix microenvironment regulates cell behavior through transactivation of receptor tyrosine kinases.

Indexed as

Amino Acid SubstitutionAnimalsChemotaxisEndothelial CellsFibronectinsHumansIntegrin beta1LiverMiceMice, KnockoutMutation, MissensePhosphorylationReceptor, Fibroblast Growth Factor, Type 1Signal Transductionsrc-Family KinasesFGFR1 protein, humanFgfr1 protein, mouseFibronectinsIntegrin beta1Receptor, Fibroblast Growth Factor, Type 1src-Family Kinases

Identifiers

PMID22247553
PMCPMC3293564
OpenAlexW1989725239

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.